Mar 17, 2020
Okayama University Research: Disrupting Blood Supply to Tumors as a New Strategy to Treat Oral Cancer
Nov 05, 2019
BioLineRx Announces BL-8040 in Combination With KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients
Oct 31, 2019
BioLineRx to Present Two Posters at the Society for Immunotherapy of Cancer (SITC) 2019
Oct 29, 2019
BioLineRx to Deliver Oral Presentation at ESMO Immuno-Oncology Congress 2019
Mar 27, 2019
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
Nov 26, 2018
Tactiva Therapeutics Announces License to Oncolytic Vaccinia Virus Armed With CXCR4 Antagonist for Treatment of Ovarian Cancer
Oct 03, 2018
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
Aug 07, 2018
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
May 17, 2018
BioLineRx to Present Overall Survival Data at EHA from Phase 2a Study of BL-8040 in r/r AML Patients
May 17, 2018
BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
Jan 23, 2018
BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
Jan 17, 2018
BioLineRx Announces Partial Monotherapy Results from Phase 2a COMBAT Study in Pancreatic Cancer
Dec 21, 2017
BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
Dec 05, 2017
BioLineRx Ltd. Hosts Investor Breakfast Meeting in NY
Dec 04, 2017
BioLineRx Reports Overall Survival Results From Long-term Follow-up of Phase 2a Trial in r/r AML
Nov 02, 2017
BioLineRx Announces Oral Presentation at ASH of Data Supporting BL-8040 as Robust Mobilizer of Hematopoietic Stem Cells (HSC) Associated with Long-Term Engraftment
Oct 18, 2017
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration
Aug 29, 2017
Stromal Cell Derived Factor 1 (C-X-C Motif Chemokine 12 or Intercrine Reduced In Hepatomas or SDF1 or Pre B Cell Growth Stimulating Factor or CXCL12) - Pipeline Review, H2 2017
Aug 21, 2017
BioLineRx Announces Regulatory Submission of Phase 3 Registrational Study for BL-8040 in Stem Cell Mobilization